Versartis, Inc. (NASDAQ:VSAR) has received a consensus rating of “Hold” from the twelve research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $5.63.
A number of analysts recently commented on VSAR shares. Piper Jaffray Companies cut shares of Versartis from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $26.00 to $4.00 in a research report on Friday, September 22nd. Barclays cut Versartis from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $28.00 to $4.00 in a report on Friday, September 22nd. Cowen cut Versartis from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $45.00 to $3.00 in a report on Friday, September 22nd. SunTrust Banks cut Versartis from a “buy” rating to a “hold” rating and lowered their target price for the stock from $25.00 to $4.00 in a report on Friday, September 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $14.00 target price (down previously from $34.00) on shares of Versartis in a report on Friday, September 22nd.
Shares of Versartis (NASDAQ VSAR) opened at $2.28 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52. Versartis has a 1 year low of $1.60 and a 1 year high of $24.00. The company has a market cap of $81.47, a price-to-earnings ratio of -0.58 and a beta of 2.36.
In other news, Director Srinivas Akkaraju bought 513,872 shares of the stock in a transaction on Monday, December 4th. The stock was purchased at an average price of $2.21 per share, for a total transaction of $1,135,657.12. Following the acquisition, the director now owns 14,955 shares in the company, valued at $33,050.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 2,769 shares of company stock valued at $7,061. Corporate insiders own 10.90% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Emory University bought a new position in shares of Versartis in the 2nd quarter valued at about $1,709,000. Lord Abbett & CO. LLC grew its holdings in shares of Versartis by 26.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 319,854 shares of the biopharmaceutical company’s stock valued at $5,582,000 after acquiring an additional 66,977 shares in the last quarter. First Quadrant L P CA grew its holdings in shares of Versartis by 1,253.8% in the 3rd quarter. First Quadrant L P CA now owns 120,500 shares of the biopharmaceutical company’s stock valued at $295,000 after acquiring an additional 111,599 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Versartis by 15.6% in the 2nd quarter. Northern Trust Corp now owns 420,553 shares of the biopharmaceutical company’s stock valued at $7,339,000 after acquiring an additional 56,761 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Versartis by 11.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock valued at $19,569,000 after acquiring an additional 118,894 shares in the last quarter. Institutional investors own 49.18% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/01/08/versartis-inc-vsar-receives-average-rating-of-hold-from-analysts.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.